A 44-year-old woman who has a long-standing diagnosis of SLE has been able to control her symptoms with lifestyle modifications for several years, but has presented to her care provider due to recent exacerbation. Which of the following pharmacological treatment options is her care provider most likely to rule out first?

Question

Quizplus · Accepted Answer

While NSAIDs, corticosteroids, and immunosuppressives are all noted treatment options for SLE, antiplatelet aggregators are unlikely to address the etiology or signs and symptoms of the disease. A new drug that has shown positive effects in decreasing inflammatory exacerbations for people with SLE is Belimumab, which is a monoclonal antibody that inhibits B-lymphocyte stimulator.

A 44-Year-Old Woman Who Has a Long-Standing Diagnosis of SLE